company score funding investors employees industries biz model city contact
Aqemia

Drug discovery platform.

68
$32M · Series A Wendel Growth, Bpifrance, Elaia 51 to 100 Biotech B2B Paris, France •••••••••••@aqemia.com
Tubulis

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.

68
$139M · Series B Nextech Invest, EQT Life Sciences, Andera Partners 11 to 50 Health Tech, Biotech, Deep Tech B2B Munich, Germany •••••••••••@tubulis.com
BioptimusJUST ADDED

Developer of a universal AI foundation model for biology.

68
$35M · Seed Frst, Bpifrance, Sofinnova Partners 1 to 10 AI, Biotech B2B, SaaS Paris, France •••••••••••@bioptimus.com
Adionics

Eco-friendly liquid-liquid direct lithium extraction (DLE) process developer.

64
$27M · Series B Celeste Management, Sociedad Quimica Y Minera (SQM), Bpifrance 11 to 50 Climate Tech & Green Tech, Biotech B2B Paris, France •••••••••••@adionics.com
Baseimmune

AI vaccine algorithm developer.

64
$11M · Series A Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures 1 to 10 AI, Biotech B2B, SaaS London, UK •••••••••••@baseimmune.co.uk
Causaly

Biomedical research discovery tool.

64
$60M · Series B ICONIQ Growth, Index Ventures, Pentech Ventures 51 to 100 Health Tech, AI, Biotech, Pharma B2B, SaaS London, UK •••••••••••@causaly.com
Onego Bio HIRING

Animal-free egg protein producer for food manufacturers.

64
$28M · Series A EIT Food, Agronomics, Tesi 11 to 50 Foodtech, Biotech B2B Helsinki, Finland •••••••••••@onego.bio
Beacon Therapeutics

Oophthalmic gene therapy company to treat blinding retinal illnesses.

64
$120M · Series A Syncona Partners LLP 1 to 10 Health Tech, Biotech London, UK •••••••••••@beacontx.com
Apollo Therapeutics

Portfolio of pharmaceutical research and discovery.

64
$33M · Series C Patient Square Capital, Rock Springs Capital, M&G Investments 1 to 10 Biotech, Pharma London, UK •••••••••••@apollotherapeutics.com
Eligo Bioscience

Gene-editing platform.

64
$30M · Series B Sanofi Ventures, Khosla Ventures, Bpifrance 11 to 50 Health Tech, Biotech Paris, France •••••••••••@eligo.bio
Calluna Pharma

Developer of therapies for inflammatory and fibrotic diseases.

64
$81M · Series A Sarsia, p53, Forbion Capital Partners 11 to 50 Biotech, Pharma Oslo, Norway •••••••••••@callunapharma.com
IMU Biosciences

AI platform to map the human immune system.

64
$14M · Series A Life Extension Ventures, Molten Ventures 11 to 50 Health Tech, Biotech London, UK •••••••••••@imubiosciences.com
MIP DiscoveryJUST ADDED

Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies.

64
$8M · Series A Mercia Asset Management 11 to 50 Health Tech, Biotech London, UK •••••••••••@mipdiscovery.com
Cure51JUST ADDED HIRING

Cancer survivors data analysis platform.

64
$16M · Seed Hitachi Ventures, Life Extension Ventures, Sofinnova Partners 11 to 50 Biotech, Data and Analytics B2B, SaaS Paris, France •••••••••••@cure51.com
MetyosJUST ADDED HIRING

Biosensors developer to combat chronic kidney disease.

64
$2M · Pre Seed Bpifrance, Kima Ventures, Cenitz 1 to 10 Health Tech, Biotech Paris, France •••••••••••@metyos.com
SparxellJUST ADDED HIRING

Developer of sustainable plant-based pigments.

64
$3M · Seed PDS Ventures, Circular Innovation Fund, L'Oreal 1 to 10 Biotech, Manufacturing B2C London, UK •••••••••••@sparxell.com
Mnemo Therapeutics

Mnemo Therapeutics specializes in biotechnology and life science.

59
$89M · Series A Sofinnova Partners 101 to 250 Health Tech, Biotech B2B Paris, France •••••••••••@mnemo-tx.com
Mytos

Fully-automated cell manufacturing.

59
$19M · Series A Buckley Ventures, Wing Venture Capital, IQ Capital Partners 11 to 50 Biotech, Machine Learning B2B London, UK •••••••••••@mytos.bio
Orbis Medicines

Oral macrocycle drug discovery platform.

59
$28M · Seed Novo A/S, Forbion Capital Partners 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@orbismedicines.com
SparingVision

SparingVision is a biotechnology company focused development of genomic medicines for the treatment of blinding inherited retinal diseases.

59
$52M · Series A Ysios Capital 1 to 10 Health Tech, Biotech, Deep Tech B2B Paris, France •••••••••••@sparingvision.com
Complement Therapeutics

Preclinical stage treatment for geographic atrophy.

59
$78M · Series A Forbion Capital Partners, Gimv 1 to 10 Biotech London, UK •••••••••••@complementtx.com
FA Bio

Discovery and development platform of superior microbial bioproducts.

59
$6M · Series A Pymwymic, Clean Growth Fund 1 to 10 Biotech London, UK •••••••••••@fungialert.com
HEPHAISTOS-Pharma

Immunotherapies developer for cancer patient.

59
$2M · Seed Fournier-Majoie, Meusinvest (Noshaq), xista science ventures 1 to 10 Health Tech, Biotech Paris, France •••••••••••@hephaistos-pharma.fr
Paques Biomaterials

Polyhydroxyalkanoates (PHA) producer.

59
$15M · Seed NV NOM, Invest-NL 1 to 10 Biotech Amsterdam, Netherlands •••••••••••@paquesbiomaterials.nl
Stanhope AIJUST ADDED HIRING

Neuroscience-driven AI platform.

59
$2M · Seed Rockmount Capital, UCL Technology Fund, Moonfire Ventures 11 to 50 AI, Biotech B2B, SaaS London, UK •••••••••••@stanhopeai.com
NeurosterixJUST ADDED HIRING

Advanced allosteric modulator therapeutics developer for neurological disorders.

56
$63M · Series A Xontogeny, Perceptive Advisors, Acorn Bioventures 1 to 10 Health Tech, Biotech Geneva, Switzerland •••••••••••@neurosterix.com
CatalYm

Innovative immunotherapies developer for cancer patients.

54
$51M Forbion Capital Partners, Vesalius Biocapital Partners, Bayern Kapital 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@catalym.com
Charm Therapeutics

CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.

54
$50M · Series A General Catalyst, Khosla Ventures 1 to 10 Health Tech, AI, Biotech, Data and Analytics B2B London, UK •••••••••••@charmtx.com
Egle Therapeutics

Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.

54
$46M Bioqube Ventures 11 to 50 Health Tech, Biotech B2B Paris, France •••••••••••@egle-tx.com
Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.

54
$3M · Series F The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Omnes Capital, Nestlé Health Science 51 to 100 Health Tech, Biotech, Deep Tech, Pharma B2B Paris, France •••••••••••@enterome.com
Eyevensys

Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases.

54
$30M · Series B Pureos Bioventures, Karista 11 to 50 Health Tech, Hardware, Biotech, Manufacturing B2B Paris, France •••••••••••@eyevensys.com
LabGenius

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.

54
$25M Kindred Capital, Atomico 51 to 100 Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing B2B London, UK •••••••••••@labgeni.us
Lindus Health

Clinical trials platform.

54
$18M · Series A Valar Ventures, Seedcamp, Atomico 11 to 50 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@lindushealth.com
MinervaX

Developer of prophylactic vaccine against Group B Streptococcus.

54
$57M · Series C EQT Partners, Novo A/S, OrbiMed 1 to 10 Health Tech, Biotech B2B Copenhagen, Denmark •••••••••••@minervax.com
Ori Biotech

Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments.

54
$30M · Series A Kindred Capital, Octopus Ventures, Amadeus Capital 1 to 10 Health Tech, Biotech, Manufacturing B2B London, UK •••••••••••@oribiotech.com
Pear Bio

Cancer treatment predictor software.

54
$14M · Series A Hoxton Ventures, Octopus Ventures, Fly Ventures 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@pearbio.com
Quell Therapeutics

Quell Therapeutics is a cell therapy company

54
$45M · Series A AlbionVC, Point72 Ventures 101 to 250 Health Tech, Edtech, Biotech, Manufacturing B2B London, UK •••••••••••@quell-tx.com
ReViral

ReViral is a biotechnology company that develops and offers antiviral therapies for patients.

54
$44M · Series C Novo A/S, Andera Partners 11 to 50 Health Tech, Biotech, Pharma B2B London, UK •••••••••••@reviral.co.uk
Tropic Biosciences

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

54
$28M · Series B Future Planet Capital 11 to 50 Agritech, Biotech, Deep Tech, Manufacturing B2B London, UK •••••••••••@tropicbioscience.com
Farmless

Fermentation process to produce protein from animals.

54
$5M · Seed Voyager Ventures, Revent, World Fund 1 to 10 Foodtech, Biotech B2C Amsterdam, Netherlands •••••••••••@farmless.com
Hypervision Surgical

Precision software for eye surgery.

54
$8M · Seed Redalpine 1 to 10 Health Tech, Biotech London, UK •••••••••••@hypervisionsurgical.com
AAVantgarde Bio

Gene therapies for inherited retinal disorders.

54
$65M · Series A Forbion Capital Partners 1 to 10 Biotech Milan, Italy •••••••••••@aavantgardebio.com
Multiomic Health

Precision therapeutics discovery platform.

54
$6M · Seed Hoxton Ventures 11 to 50 Biotech B2B London, UK •••••••••••@multiomic.uk
Astraveus

Automated bioprocessing system for the production of cell and gene therapies.

54
$18M · Seed AdBio Partners 11 to 50 Biotech Paris, France •••••••••••@astraveus.com
Umedeor

Platform to automate the clinical studies process.

54
$12M · Series A Playfair, Delin Ventures, 11.2 Capital 11 to 50 Health Tech, Biotech B2B London, UK •••••••••••@umed.io
Flarin

Patent-protected anti-inflammatory painkiller.

54
$6M · Series A ITV AdVentures 1 to 10 Biotech, Pharma B2C London, UK •••••••••••@flarin.co.uk
Genomes

User-owned genomics database platform.

54
$20M · Series A GEM Digital 1 to 10 Health Tech, Biotech B2C London, UK •••••••••••@genomes.io
Gradient Denervation Technologies

Medical devices for a transvascular treatment of pulmonary hypertension.

54
$14M · Series A Sofinnova Partners, Asabys Partners 1 to 10 Health Tech, Biotech Paris, France •••••••••••@gradientdenervation.com
Laverock Therapeutics

Gene silencing platform for the creation of programmable, allogeneic cell therapies.

54
$16M · Seed Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund 1 to 10 Health Tech, Biotech London, UK •••••••••••@laverocktx.com
ImmuONE

3D human lung model developer.

54
$2M · Seed Pioneer Group, Mercia Asset Management, Midlands Engine Investment Fund 11 to 50 Biotech, Deep Tech London, UK •••••••••••@immuone.com
Nūmi

Breast milk producer from cell-cultured mammary glands.

54
$3M · Pre Seed Heartcore, Kima Ventures, Kost Capital 1 to 10 Biotech, FamilyTech & Parenting B2C Paris, France •••••••••••@numi.life
Floy

AI platform for radiology diagnostics.

54
$5M · Seed xdeck, 10x Founders 11 to 50 Health Tech, Biotech Munich, Germany •••••••••••@floy.com
Samabriva

Biomanufacturer of complex molecules.

54
$4M · Seed Meusinvest (Noshaq) 1 to 10 Biotech, Manufacturing Paris, France •••••••••••@samabriva.com
Hoba Therapeutics

Therapeutic protein developer for chronic neuropathic pain.

54
$24M · Series A Medical Incubator Japan, Borean Innovation, Novo A/S 1 to 10 Health Tech, Biotech Copenhagen, Denmark •••••••••••@hobatherapeutics.com
Sable bioJUST ADDED

AI-powered drug testing platform.

54
$1M · Pre Seed Seedcamp, Episode 1 1 to 10 AI, Biotech London, UK •••••••••••@sablebio.com
Nouscom HIRING

Viral vector-based cancer vaccines developer.

51
$82M · Series C Bpifrance, 5AM Ventures, Abingworth 1 to 10 Health Tech, Biotech B2C Basel, Switzerland •••••••••••@nouscom.com
Achilles Therapeutics

Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

50
$17M · Seed AlbionVC, Boxer Capital, Syncona Partners LLP 101 to 250 Health Tech, Biotech B2B London, UK •••••••••••@achillestx.com
ADmit Therapeutics

Early detection of Alzheimer's disease (AD) technology.

50
$5M · Series A EIC Accelerator, WA4STEAM, Ship2B 1 to 10 Health Tech, Biotech, Pharma B2B Barcelona, Spain •••••••••••@admit-therapeutics.com
AMSilk

Developer of bio-fabricated silk protein materials.

50
$27M · Series C Novo A/S 11 to 50 Health Tech, Biotech, Manufacturing B2B Munich, Germany •••••••••••@amsilk.com
Bactolife

Producer of gut health binding proteins.

50
$32M · Series A Bill & Melinda Gates Foundation, Novo A/S 1 to 10 Biotech, Pharma B2B Copenhagen, Denmark •••••••••••@bactolife.com
Daye

Daye is a gynecological health company that creates products and services for vaginal treatment.

50
$5M · Seed Index Ventures, Khosla Ventures, Kindred Capital 11 to 50 Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis B2C London, UK •••••••••••@yourdaye.com
EnginZyme

Bio alternative to fossil-based and energy–intensive chemical production.

50
$22M · Series B Sofinnova Partners, SEB Venture Capital, Industrifonden 51 to 100 Health Tech, Biotech B2B Stockholm, Sweden •••••••••••@enginzyme.com
Ermium Therapeutics

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases.

50
$6M · Series A Fountain Healthcare Partners 1 to 10 Health Tech, Biotech, Pharma B2B Paris, France •••••••••••@ermium.com
Hemab

Treatments for genetic bleeding disorders.

50
$135M · Series B Novo A/S, HealthCap 1 to 10 Health Tech, Biotech, Deep Tech, Pharma B2B Copenhagen, Denmark •••••••••••@hemab.com
Kuano

Quantum simulation platform for drug discovery.

50
$2M · Seed Ascension Ventures, ACF Investors 1 to 10 Health Tech, Biotech B2B, SaaS London, UK •••••••••••@kuano.ai
Leyden Labs

Manufacturer of medicines to protect from the threat of respiratory viruses

50
$47M SoftBank Group, GV 11 to 50 Health Tech, Biotech, Deep Tech B2B Amsterdam, Netherlands •••••••••••@leydenlabs.com
Myricx Pharma

Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors.

50
$6M · Seed Sofinnova Partners 1 to 10 Health Tech, Biotech, Deep Tech, Pharma B2B London, UK •••••••••••@myricxpharma.com
nextProtein

nextProtein develops a new large-scale technology that produces a sustainable source of protein.

50
$11M · Series A Blue Oceans Partners 11 to 50 Climate Tech & Green Tech, Agritech, Foodtech, Biotech, Manufacturing B2B Paris, France •••••••••••@nextprotein.co
NorthSea Therapeutics

Innovative therapeutic drugs to treat inflammatory, metabolic and liver diseases.

50
$27M · Series A Sofinnova Partners, Novo A/S, Forbion Capital Partners 11 to 50 Health Tech, Biotech B2B Amsterdam, Netherlands •••••••••••@northseatherapeutics.com
OTHER INDUSTRIES
Other Biotech startups by location